# OnCo record rejuv-second-choices-made-at-treatment (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/rejuv-second-choices-made-at-treatment/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "rejuv-second-choices-made-at-treatment" ;
  schema:name "Choices made at the time of treatment that change the second cancer risk"@en ;
  schema:alternateName "De-escalation and late effects"@en, "Treatment choice and second cancers"@en, "Omitting radiotherapy"@en ;
  schema:description "Some of this risk is a decision rather than a fate. Where two treatments cure equally well and one carries less late risk, that is a conversation to have before treatment starts. Trials have settled several: a different partner drug in myeloma, a lower cyclophosphamide dose in breast cancer, brachytherapy rather than external beam."@en ;
  schema:url <https://onco.cc/terms/rejuv-second-choices-made-at-treatment/> ;
  schema:dateModified "2026-10-02"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Radiation-induced_cancer> ;
  schema:citation <https://doi.org/10.1016/S1470-2045(13)70609-0>, <https://doi.org/10.1200/JCO.2003.03.114>, <https://doi.org/10.1136/bmj.i851>, <https://doi.org/10.1056/NEJMoa1408648>, <https://doi.org/10.1200/JCO.21.00408>, <https://doi.org/10.1093/jnci/dji278>, <https://doi.org/10.1093/jnci/86.7.527> ;
  onco:tag "rejuvenation", "survivorship", "second-cancers", "radiotherapy", "chemotherapy" ;
  onco:related <https://onco.cc/terms/rejuv-second-cancers-overview/>, <https://onco.cc/terms/rejuv-second-platinum-and-parp-inhibitors/>, <https://onco.cc/terms/rejuv-second-alkylating-agents-and-myeloid-neoplasms/>, <https://onco.cc/terms/rejuv-second-radiotherapy-dose-field-and-age/>, <https://onco.cc/terms/second-primary-bladder-after-cyclophosphamide/>, <https://onco.cc/terms/second-primary-bowel-after-abdominal-radiotherapy/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/testicular/>, <https://onco.cc/cancers/seminoma/>, <https://onco.cc/cancers/endometrial/> ;
  onco:sections <https://onco.cc/fronts/rejuvenation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/terms/deep-inspiration-breath-hold/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:drugs <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/melphalan/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:terms <https://onco.cc/terms/secondary-malignancy/>, <https://onco.cc/terms/second-cancers-after-radiotherapy/>, <https://onco.cc/terms/late-effects/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-dose-optimisation/>, <https://onco.cc/bottlenecks/b-surgery-radiation-innovation/> .